vTv Therapeutics (VTVT) Enterprise Value (2014 - 2026)

vTv Therapeutics has disclosed Enterprise Value across 13 years of filings, most recently posting -$98.1 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$98.1 million, down 226.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$98.1 million (down 226.06% YoY), and the FY2025 annual result was -$88.9 million, down 156.07% from the prior year.
• Enterprise Value came in at -$98.1 million for Q1 2026 at vTv Therapeutics, down from -$88.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $8.9 million in Q3 2022 to a low of -$98.5 million in Q3 2025.
• The 5-year median for Enterprise Value is -$26.3 million (2025), against an average of -$29.0 million.
• Across the five-year window, Enterprise Value jumped 402.8% in 2023 and tumbled 6103.69% in 2024, its largest moves.
• vTv Therapeutics' Enterprise Value stood at $4.4 million in 2022, then sank by 314.31% to -$9.5 million in 2023, then slumped by 265.15% to -$34.7 million in 2024, then plunged by 156.07% to -$88.9 million in 2025, then slipped by 10.29% to -$98.1 million in 2026.
• The last three Enterprise Value figures came in at -$98.1 million (Q1 2026), -$88.9 million (Q4 2025), and -$98.5 million (Q3 2025), per Business Quant data.